Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06549257
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-03-12
Brief Title:
Assessing the Safety Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines Pfs25-IMX313 and Pfs4548 Administered Alone and in Combination in Matrix-M Adjuvant
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase Ib Open Label Clinical Trial of the Safety Immunogenicity and ex Vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines Pfs25-IMX313 and Pfs4548 Administered Alone and in Combination in Matrix-M Adjuvant in Healthy Adults Adolescents and Young Children in Burkina Faso
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Assessing the safety immunogenicity and ex-vivo efficacy of two transmission blocking vaccines Pfs25-IMX313 in Matrix M and Pfs4845 in Matrix M alone and co-administered in Burkina Faso in 18-45 years 12-17 years and 05-11 year olds
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None